Retatrutide vs Tirzepatide vs Semaglutide: 2026 GLP-1 Comparison

The short answer

If you're researching the GLP-1 class in 2026, the three compounds that matter are Retatrutide, Tirzepatide, and Semaglutide. The trial data is now mature enough to rank them by weight reduction:

• Retatrutide 12mg weekly: -24.2% at 48 weeks (Phase 2)
• Tirzepatide 15mg weekly: -20.9% at 72 weeks (SURMOUNT-1)
• Semaglutide 2.4mg weekly: -14.9% at 68 weeks (STEP-1)

All three are once-weekly subcutaneous injections. The right choice depends on what you're actually trying to answer: maximum efficacy (Retatrutide), Phase 3 + FDA approval (Tirzepatide), or the longest cardiovascular outcomes track record (Semaglutide).

This article walks through every variable that matters (mechanism, efficacy, tolerability, half-life, dose range, and cost) so you can pick the compound that fits your research question.

The three mechanisms

Each compound activates a different combination of incretin and counter-regulatory receptors. More receptors does not automatically mean more efficacy, but in this class it has.

What each receptor contributes

GLP-1 receptor is the backbone of the class. Activation reduces appetite, slows gastric emptying, and amplifies glucose-dependent insulin secretion. This is the "eat less" signal that every compound in this family shares.

GIP receptor is the second incretin. On its own, GIP agonism is modest, but stacked on top of GLP-1, it amplifies insulin response and appears to shift energy expenditure upward. Tirzepatide is the proof that adding GIP on top of GLP-1 delivers meaningfully more weight loss.

Glucagon receptor is the wildcard. Traditionally, glucagon raises blood sugar (it's the counter-regulatory hormone to insulin), which sounds like a problem for a weight-loss compound. But when paired with strong GLP-1/GIP action, glucagon agonism drives increased energy expenditure (the body burns more at rest) while the incretin pathways keep glucose control intact. Retatrutide is the first compound to pull this off at scale.

The takeaway: Semaglutide is an appetite drug, Tirzepatide is an appetite-plus-metabolic drug, and Retatrutide is an appetite-plus-metabolic-plus-burn drug.

Head-to-head efficacy

Direct comparative trial data is limited; only the SURPASS-2 trial has run a head-to-head (Tirzepatide vs Semaglutide). For Retatrutide, we rely on the Phase 2 obesity trial (Jastreboff et al., NEJM 2023). Normalizing the numbers to the maximum approved or studied dose:

A few things worth flagging about this table. First, the Retatrutide 24.2% figure is at 48 weeks, and the weight loss curve was still trending down when the trial ended, so the number may be conservative for a longer protocol. Second, Tirzepatide's SURMOUNT-1 data at 72 weeks is the most mature efficacy dataset in the class. Third, Semaglutide's 14.9% is often quoted as "only" 14.9% in 2026 conversations, but in historical context this was the biggest weight loss number ever seen in a pharmaceutical trial until Tirzepatide and Retatrutide arrived.

You can model each compound's plasma dynamics in the half-life visualizer.

Side effect profile

All three compounds share the GLP-1 class side effect profile: nausea, diarrhea, vomiting, constipation. The pattern is consistent: effects peak during titration and attenuate with continued use.

The noteworthy number is nausea. Retatrutide's ~35% nausea rate at 12mg is meaningfully higher than the other two, but the discontinuation rate is essentially the same, suggesting the nausea is transient and manageable rather than protocol-ending. This is consistent with the broader pattern in this class: more efficacy tends to mean more GI adjustment during titration, but adherence numbers converge once steady state is reached.

For Retatrutide specifically, the 12-week titration protocol mirrors the Phase 2 dose ladder and is designed to minimize the early-cycle nausea spike.

Half-life and dosing practicalities

All three compounds are engineered for once-weekly subcutaneous dosing. The mechanisms are different:

• Semaglutide uses fatty acid acylation for albumin binding, yielding a ~7 day half-life.
• Tirzepatide also uses fatty acid acylation (a C20 diacid moiety), yielding a ~5 day half-life.
• Retatrutide uses a similar acylation strategy, yielding a ~6 day half-life.

In practice, all three reach steady state within 4-5 weekly doses. Semaglutide has the flattest peak-trough profile; Tirzepatide has slightly more oscillation; Retatrutide sits in between.

Dose ranges

• Semaglutide: 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg weekly (16-20 week titration)
• Tirzepatide: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly (20 week titration)
• Retatrutide: 2 → 4 → 8 → 12 mg weekly (12 week titration in Phase 2)

Higher doses exist for Retatrutide (14mg was studied) but did not produce additional efficacy beyond 12mg. The weight loss curve plateaued.

For reconstitution math at each dose level, use the reconstitution calculator.

Cost, availability, and research access

As of early 2026:

• Semaglutide is approved as Ozempic (T2D) and Wegovy (weight management). Extensive commercial supply. Retail pricing is the highest barrier; insurance coverage is variable for weight management indications.
• Tirzepatide is approved as Mounjaro (T2D) and Zepbound (weight management). Approved in 2022-2023.
• Retatrutide is not FDA approved. The Phase 3 TRIUMPH program is ongoing (TRIUMPH-1 obesity, TRIUMPH-2 T2D, TRIUMPH-3 CVD outcomes, TRIUMPH-4 MASLD). Lilly has indicated a potential regulatory submission in late 2026 or 2027.

For research-grade compounds, all three are available from the verified partner with COA-verified purity ≥98%. See the individual peptide guides linked below for vial sizes and reconstitution protocols.

Which one should you research?

The answer depends on your endpoint.

Choose Retatrutide if:

• Maximum weight reduction is the primary endpoint
• You're studying MASLD or hepatic fat (Phase 2 Nature Medicine data)
• You're comparing the third-generation triple agonist against existing GLP-1s
• You're willing to accept the higher nausea rate during titration

Choose Tirzepatide if:

• You want completed Phase 3 data + FDA approval
• You're studying T2D glycemic control alongside weight
• You want very strong efficacy (-20.9%) with a lower GI burden than Retatrutide
• You need the head-to-head SURPASS-2 data vs Semaglutide

Choose Semaglutide if:

• Cardiovascular outcomes are part of the research question (SELECT trial: 20% MACE reduction)
• You need the longest commercial safety record
• You're modeling long-term adherence and real-world effectiveness
• You want the most dose-titration flexibility at the low end

You can also consider Cagrilintide as an amylin agonist that's often studied in combination with Semaglutide (CagriSema). It's a different mechanism but lives in the same weight management research space.

For deeper dives, see:

• Tirzepatide vs Semaglutide: the 2026 head-to-head
• Retatrutide explained: why it's the most effective weight peptide yet
• 12-week Retatrutide titration protocol

Research access

All three compounds are available from the verified partner at research-grade purity with 50% off using code ENHANCED. COA-verified, US-based shipping, discreet packaging.

• Retatrutide research guide →
• Tirzepatide research guide →
• Semaglutide research guide →
• Cagrilintide research guide →
• Reconstitution calculator →
• Half-life visualizer →

Disclaimer

The information in this article is provided for research and educational purposes only. None of these compounds are approved for general human use as described, and nothing here is medical advice. Consult a qualified healthcare professional before any decision involving any of these compounds.